New cancer drug begins first human testing
NCT ID NCT06672185
Summary
This is the first study in humans to test a new drug called ARC101 for people with advanced solid tumors. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer Research Centre
RECRUITINGVancouver, British Columbia, V5Z 0B4, Canada
Contact
-
Cabrini Health Research
RECRUITINGMalvern, Victoria, 3144, Australia
Contact
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
-
Rambam Medical Center
RECRUITINGHaifa, 3109601, Israel
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
START San Antonio, LLC.
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Sheba Medical Center
RECRUITINGRamat Gan, 52621, Israel
Contact
-
Sourasky Medical Center
RECRUITINGTel Aviv, 6423906, Israel
Contact
-
Sunshine Coast University Private Hospital
RECRUITINGBirtinya, Queensland, 4575, Australia
Contact
-
The Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact
Conditions
Explore the condition pages connected to this study.